Biological Science Inc.

Science, Japan

Biological Science Inc.

Science, Japan
SEARCH FILTERS
Time filter
Source Type

News Article | May 4, 2017
Site: www.thefishsite.com

Multinational feed additive producer Nutriad announced the appointment of Dr Wei Wang as Technical Manager for China. As part of an ongoing strategy to increase its presence in this dynamic market, Nutriad continues to invest in building technical and commercial support teams in China, allowing them to further improve their constant engagement and support to customers. BK Chew, APAC Director Nutriad, commented "China is the main growth engine within APAC and the appointment of Dr Wang will enable increased technical support for our applications in mycotoxin management and gut health.” Dr. Wei completed a total of 10 years of studies in animal nutrition, obtaining a BSc in Animal Science at Southwest University of Science & Technology, a MSc in Swine Nutrition at Sichuan Agriculture University and PhD in Applied Biological Science, Swine Nutrition at Ghent University. Dr Wang said, “I have always been fascinated by converting scientific knowledge on animal nutrition and health into practical solutions. As such I have admired Nutriad from the outside for many years and am excited to now become part of the Chinese team and support the company on its next steps in China.” Nutriad, headquartered in Belgium, provides feed additives and services to over 80 countries worldwide through a network of own offices and distributors, supported by 4 application laboratories and 5 manufacturing facilities located on 3 continents. Find out more at www.nutriad.com


News Article | May 18, 2017
Site: news.yahoo.com

According to a new study, the famed Tyrannosaurus rex had quite the bite. With these powerful jaws, a T. rex could demolish bones with forces equaling the weight of three small cars. The predator-scavanger could bite down with nearly 8,000 pounds of force, more than twice the bite force of the largest living crocodiles, the modern bite force kings. Eating bones, known as extreme osteophagy in scientific communities, is not uncommon today, but it usually happens among carnivorous mammals like wolves or hyenas. Reptiles generally do not have the tooth structure to break down bone. "It was this bone-crunching acumen that helped T. rex to more fully exploit the carcasses of large horned-dinosaurs and duck-billed hadrosaurids whose bones, rich in mineral salts and marrow, were unavailable to smaller, less equipped carnivorous dinosaurs," says Paul Gignac, assistant professor of Anatomy and Vertebrate Paleontology at Oklahoma State. This joint study study between Florida State and Oklahoma State also shows the power of each individual tooth. A tyrannosaurus tooth could generate 431,000 pounds per square inch. This allowed the dinosaur to bite down repetitively on a bone like a mammal would. The splintering bones would likely sometimes explode out of the the giant reptile's mouth. After studying birds and crocodilians, the scientists realized that it wasn't just strong jaw muscles that allowed the might beast to destroy bone. It was also how that force was transferred to the teeth itself, a metric they called tooth pressure. "Having high bite force doesn't necessarily mean an animal can puncture hide or pulverize bone, tooth pressure is the biomechanically more relevant parameter," says Florida State Professor of Biological Science Gregory Erickson. "It is like assuming a 600 horsepower engine guarantees speed. In a Ferrari, sure, but not for a dump truck." The T. Rex's celebrity status, which began when the dinosaur first was discovered in 1905, affords it a unique place among paleontological studies. Many, like the late palentologist Robert Bakker, attribute it to that spectacular name, Tyrannosaurus, which just rolls off the tongue. This close reading of its bone-destroying abilities shows that it had the bite to live up to the hype. You Might Also Like


News Article | April 21, 2017
Site: motherboard.vice.com

Let's talk about this video of caterpillars walking in absurd single-file. Is this another case of nature trying to tell us it's time to get off this planet? There are many videos from people capturing this phenomenon in their own backyards, each narrating with varying degrees of "What the fuck?" Why do they do this? What are they plotting? How are they so organized? It's part of the life cycle of Thaumetopoea pityocampa, or pine processionary caterpillar, a species of moth that's native to the Mediterranean region, North Africa and some of the Middle East and southern Europe. Warming winters and climate change are bringing them farther north. Although they do lay down a sweet line of pheromones as they scoot along, this is not, as one might suspect, a caterpillar fuck-train. They're marching toward a pupation site, where they can bury themselves on the soil and form cocoons. Each caterpillar is drawn forward by the ass of the caterpillar ahead of it. The leader is typically a future female. As many as three hundred caterpillars have been observed marching in one line like this, according to a blog post written by Terrence D. Fitzgerald, Professor of Biological Science at State University of New York at Cortland. French entomologist Jean-Henri Fabre studied them extensively, and wrote colorful descriptions of their behavior in his 1916 book, The Life of the Caterpillar: "They proceed in single file, in a continuous row, each touching with its head the rear of the one in front of it... No Greek theoria winding its way to the Eleusinian festivals was ever more orderly. Hence the name of Processionary given to the gnawer of the pine." Fabre experimented with their march, arranging them so that they'd walk in a circle, to see how long it would take the "leader" to realize its mistake and correct course. He assumed it would take minutes or hours, but what happened is kind of fucked up: They walked in a circle for a more than a week. "The headless file has no liberty left, no will; it has become mere clock-work," he wrote. Take what you will from that very obvious metaphor for humanity's own futility. Subscribe to Science Solved It, Motherboard's new show about the greatest mysteries that were solved by science.


News Article | May 17, 2017
Site: www.rdmag.com

The giant Tyrannosaurus rex pulverized bones by biting down with forces equaling the weight of three small cars while simultaneously generating world record tooth pressures, according to a new study by a Florida State University-Oklahoma State University research team. In a study published today in Scientific Reports, Florida State University Professor of Biological Science Gregory Erickson and Paul Gignac, assistant professor of Anatomy and Vertebrate Paleontology at Oklahoma State University Center for Health Sciences, explain how T. rex could pulverize bones -- a capacity known as extreme osteophagy that is typically seen in living carnivorous mammals such as wolves and hyenas, but not reptiles whose teeth do not allow for chewing up bones. Erickson and Gignac found that this prehistoric reptile could chow down with nearly 8,000 pounds of force, which is more than two times greater than the bite force of the largest living crocodiles -- today's bite force champions. At the same time, their long, conical teeth generated an astounding 431,000 pounds per square inch of bone-failing tooth pressures. This allowed T. rex to drive open cracks in bone during repetitive, mammal-like biting and produce high-pressure fracture arcades, leading to a catastrophic explosion of some bones. "It was this bone-crunching acumen that helped T. rex to more fully exploit the carcasses of large horned-dinosaurs and duck-billed hadrosaurids whose bones, rich in mineral salts and marrow, were unavailable to smaller, less equipped carnivorous dinosaurs," Gignac said. The researchers built on their extensive experience testing and modeling how the musculature of living crocodilians, which are close relatives of dinosaurs, contribute to bite forces. They then compared the results with birds, which are modern-day dinosaurs, and generated a model for T. rex. From their work on crocodilians, they realized that high bite forces were only part of the story. To understand how the giant dinosaur consumed bone, Erickson and Gignac also needed to understand how those forces were transmitted through the teeth, a measurement they call tooth pressure. "Having high bite force doesn't necessarily mean an animal can puncture hide or pulverize bone, tooth pressure is the biomechanically more relevant parameter," Erickson said. "It is like assuming a 600 horsepower engine guarantees speed. In a Ferrari, sure, but not for a dump truck." In current day, well-known bone crunchers like spotted hyenas and gray wolves have occluding teeth that are used to finely fragment long bones for access to the marrow inside -- a hallmark feature of mammalian osteophagy. Tyrannosaurus rex appears to be unique among reptiles for achieving this mammal-like ability but without specialized, occluding dentition. The new study is one of several by the authors and their colleagues that now show how sophisticated feeding abilities, most like those of modern mammals and their immediate ancestors, actually first appeared in reptiles during the Age of the Dinosaurs.


TALLAHASSEE, Fla. -- The giant Tyrannosaurus rex pulverized bones by biting down with forces equaling the weight of three small cars while simultaneously generating world record tooth pressures, according to a new study by a Florida State University-Oklahoma State University research team. In a study published today in Scientific Reports, Florida State University Professor of Biological Science Gregory Erickson and Paul Gignac, assistant professor of Anatomy and Vertebrate Paleontology at Oklahoma State University Center for Health Sciences, explain how T. rex could pulverize bones -- a capacity known as extreme osteophagy that is typically seen in living carnivorous mammals such as wolves and hyenas, but not reptiles whose teeth do not allow for chewing up bones. Erickson and Gignac found that this prehistoric reptile could chow down with nearly 8,000 pounds of force, which is more than two times greater than the bite force of the largest living crocodiles -- today's bite force champions. At the same time, their long, conical teeth generated an astounding 431,000 pounds per square inch of bone-failing tooth pressures. This allowed T. rex to drive open cracks in bone during repetitive, mammal-like biting and produce high-pressure fracture arcades, leading to a catastrophic explosion of some bones. "It was this bone-crunching acumen that helped T. rex to more fully exploit the carcasses of large horned-dinosaurs and duck-billed hadrosaurids whose bones, rich in mineral salts and marrow, were unavailable to smaller, less equipped carnivorous dinosaurs," Gignac said. The researchers built on their extensive experience testing and modeling how the musculature of living crocodilians, which are close relatives of dinosaurs, contribute to bite forces. They then compared the results with birds, which are modern-day dinosaurs, and generated a model for T. rex. From their work on crocodilians, they realized that high bite forces were only part of the story. To understand how the giant dinosaur consumed bone, Erickson and Gignac also needed to understand how those forces were transmitted through the teeth, a measurement they call tooth pressure. "Having high bite force doesn't necessarily mean an animal can puncture hide or pulverize bone, tooth pressure is the biomechanically more relevant parameter," Erickson said. "It is like assuming a 600 horsepower engine guarantees speed. In a Ferrari, sure, but not for a dump truck." In current day, well-known bone crunchers like spotted hyenas and gray wolves have occluding teeth that are used to finely fragment long bones for access to the marrow inside -- a hallmark feature of mammalian osteophagy. Tyrannosaurus rex appears to be unique among reptiles for achieving this mammal-like ability but without specialized, occluding dentition. The new study is one of several by the authors and their colleagues that now show how sophisticated feeding abilities, most like those of modern mammals and their immediate ancestors, actually first appeared in reptiles during the Age of the Dinosaurs. This work was supported by grants from the National Science Foundation and the National Geographic Society.


News Article | May 17, 2017
Site: www.chromatographytechniques.com

The giant Tyrannosaurus rex pulverized bones by biting down with forces equaling the weight of three small cars while simultaneously generating world record tooth pressures, according to a new study by a Florida State University-Oklahoma State University research team. In a study published today in Scientific Reports, Florida State University Professor of Biological Science Gregory Erickson and Paul Gignac, assistant professor of Anatomy and Vertebrate Paleontology at Oklahoma State University Center for Health Sciences, explain how T. rex could pulverize bones — a capacity known as extreme osteophagy that is typically seen in living carnivorous mammals such as wolves and hyenas, but not reptiles whose teeth do not allow for chewing up bones. Erickson and Gignac found that this prehistoric reptile could chow down with nearly 8,000 pounds of force, which is more than two times greater than the bite force of the largest living crocodiles — today’s bite force champions. At the same time, their long, conical teeth generated an astounding 431,000 pounds per square inch of bone-failing tooth pressures. This allowed T. rex to drive open cracks in bone during repetitive, mammal-like biting and produce high-pressure fracture arcades, leading to a catastrophic explosion of some bones. “It was this bone-crunching acumen that helped T. rex to more fully exploit the carcasses of large horned-dinosaurs and duck-billed hadrosaurids whose bones, rich in mineral salts and marrow, were unavailable to smaller, less equipped carnivorous dinosaurs,” Gignac said. The researchers built on their extensive experience testing and modeling how the musculature of living crocodilians, which are close relatives of dinosaurs, contribute to bite forces. They then compared the results with birds, which are modern-day dinosaurs, and generated a model for T. rex. From their work on crocodilians, they realized that high bite forces were only part of the story. To understand how the giant dinosaur consumed bone, Erickson and Gignac also needed to understand how those forces were transmitted through the teeth, a measurement they call tooth pressure. “Having high bite force doesn’t necessarily mean an animal can puncture hide or pulverize bone, tooth pressure is the biomechanically more relevant parameter,” Erickson said. “It is like assuming a 600 horsepower engine guarantees speed. In a Ferrari, sure, but not for a dump truck.” In current day, well-known bone crunchers like spotted hyenas and gray wolves have occluding teeth that are used to finely fragment long bones for access to the marrow inside — a hallmark feature of mammalian osteophagy. Tyrannosaurus rex appears to be unique among reptiles for achieving this mammal-like ability but without specialized, occluding dentition. The new study is one of several by the authors and their colleagues that now show how sophisticated feeding abilities, most like those of modern mammals and their immediate ancestors, actually first appeared in reptiles during the Age of the Dinosaurs.


GENFIT: CONVENING NOTICE TO THE ORDINARY AND EXTRAORDINARY SHAREHOLDERS MEETING ON JUNE 16, 2017 Lille (France), Cambridge (Massachusetts, United States), May 12, 2017 - GENFIT (Euronext: GNFT - ISIN: FR0004163111), a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announced that it has published today in today's French legal announcements bulletin (Bulletin des Annonces Légales Obligatoires) its convening notice to the Ordinary and Extraordinary Shareholders' Meeting to be held on Friday, June 16, 2017 at 10:30 am at the University of Lille College of Pharmaceutical and Biological Science located at Parc Eurasanté, 3, rue du Professeur Laguesse in Lille (59000), France. As indicated in its press release on April 24, the shareholders will be invited to vote on the change in the type of administration of the Company, moving from a two-tiered board (Supervisory Board and Executive Board) to a single board structure (Board of Directors). The Company considers that this change will allow it to be closer to international standards and to welcome the expert board members whom it wishes to recruit to accompany its development in the years to come. The Ordinary and Extraordinary Shareholders' Meeting will also be the occasion to implement the provisions of the "Copé-Zimmermann" law (relating to the balanced representation of men and women on corporate boards), and the shareholders will vote on the proposed nomination of Ms. Catherine Larue and Ms. Anne-Hélène Monsellato as directors of the Company.  Additional biographical information, including the experience and expertise of these candidates in included below. As also indicated in the April 24, 2017 press release, and subject to the approval of the shareholders of the change in the type of administration of the Company and the composition of the new Board of Directors, the current Chairman of the Executive Board is proposed to be appointed Chairman of the Board of Directors and Chief Executive Officer of the Company. In addition to the usual items on the agenda related to the review of the financial statements and the different reports of the Executive and Supervisory Boards and the Statutory Auditors for the 2016 fiscal year, the Executive Board is proposing a certain number of alternative draft resolutions that differ depending on the decision of the shareholders with respect to the change in type of administration of the Company.  Depending on this decision, only those draft resolutions relating to the specific type of administration chosen will be submitted to a vote of the shareholders. The resolutions submitted to the shareholders are grouped together in the following manner: Additional information is available in the convening notice dated May 12, 2017, which is available on the Company's website.  All of the documentation concerning the Ordinary and Extraordinary Shareholders' Meeting (including the Say on Pay report pursuant to the Sapin II Law) will be made available to shareholders in accordance with current regulations and also available on the Company's website by May 19, 2017. Dr. Catherine Larue has been CEO ad interim of Luxembourg Institute of Health (LIH), a biomedical research institute, since January 2016. From 2012 to end 2015, she was CEO of the Integrated Biobank of Luxembourg (IBBL), where she led the development of the biobanking strategy and new initiatives in the field of personalized medicine. Prior to joining the IBBL, Dr. Larue piloted the biomarker program at Genfit until 2012. Dr. Catherine Larue began her career as team leader at Sanofi at the Montpellier, France based R&D center in the cardiovascular research department.  She later joined Sanofi Diagnostics Pasteur Inc., in Minnesota, United States, where she ran the immunology department for three years, developing tests and instruments.  She thereafter returned to Paris, France as Director at Sanofi Diagnostics Pasteur, and then spent 11 years at the Bio-Rad group, holding different management positions.  She participated in the discovery of several innovative biomarkers and the commercialization of dozens of diagnostic products. Dr. Catherine Larue is the author of 85 articles and has filed 13 patents.  She holds a doctorate in experimental biology and an accreditation to direct research (Habilitation à Diriger la Recherche or HDR) from the University of Rouen, a degree in clinical oncology from the University of Paris VI and an executive MBA from St John's University (New York).  In 2014, she was voted Luxembourg's most inspiring woman of the year in the "Science, Technology and Research" category. Anne-Hélène Monsellato is a Certified Public Accountant in France since 2008 and graduated from EM Lyon in 1990 with a degree in Business Management. Since May 2015, she has been an independent director, the Chairman of the Audit and Risk Committee and a member of the Corporate Governance and Nomination Committee of Euronav, a Belgian crude oil tanker company listed on NYSE and Euronext Brussels.  In addition, she serves as the Vice President and Treasurer of the Mona Bismarck American Center for Art and Culture, a U.S. public foundation based in New York. From 2005 until 2013, Mrs. Monsellato served as a Partner with Ernst & Young (now EY), Paris, after having served as Auditor/Senior, Manager and Senior Manager for the firm starting in 1990. During her time at EY, she gained extensive experience in cross border listing transactions, in particular with the U.S., internal control and risk management, and was involved with several companies in the pharmaceutical and biotechnology sector. Mrs. Monsellato is an active member of the French Association of Directors (IFA) and of the selection committee of Femmes Business Angels since 2013. GENFIT is a biopharmaceutical company focused on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatment and an increasing number of patients worldwide. GENFIT's R&D efforts are focused on bringing new medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver (such as NASH - Nonalcoholic steatohepatitis) and more generally the gastro-intestinal arena. GENFIT's approach combines novel treatments and biomarkers. Its lead proprietary compound, elafibranor, is currently in a Phase 3 study. With facilities in Lille and Paris, France, and Cambridge, MA (USA), the Company has approximately 130 employees. GENFIT is a public company listed in compartment B of Euronext's regulated market in Paris (Euronext: GNFT - ISIN: FR0004163111). www.genfit.com This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, including related to biomarkers, progression of, and results of clinical data from, the RESOLVE-IT trial, review and approvals by regulatory authorities, such as the FDA or the EMA, regarding in particular, elafibranor in NASH and PBC, as well as other indications, and biomarkers, the success of any inlicensing strategies, the Company's continued ability to raise capital to fund its development, as well as those discussed or identified in the Company's public filings with the AMF, including those listed under Section 4 "Main Risks and Uncertainties" of the Company's 2016 Registration Document registered with the French Autorité des marchés financiers on April 28, 2017 under n° R.17-034, which is available on GENFIT's website (www.genfit.com) and on the website of the AMF (www.amf-france.org). Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in GENFIT in any country. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.


GENFIT: CONVENING NOTICE TO THE ORDINARY AND EXTRAORDINARY SHAREHOLDERS MEETING ON JUNE 16, 2017 Lille (France), Cambridge (Massachusetts, United States), May 12, 2017 - GENFIT (Euronext: GNFT - ISIN: FR0004163111), a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announced that it has published today in today's French legal announcements bulletin (Bulletin des Annonces Légales Obligatoires) its convening notice to the Ordinary and Extraordinary Shareholders' Meeting to be held on Friday, June 16, 2017 at 10:30 am at the University of Lille College of Pharmaceutical and Biological Science located at Parc Eurasanté, 3, rue du Professeur Laguesse in Lille (59000), France. As indicated in its press release on April 24, the shareholders will be invited to vote on the change in the type of administration of the Company, moving from a two-tiered board (Supervisory Board and Executive Board) to a single board structure (Board of Directors). The Company considers that this change will allow it to be closer to international standards and to welcome the expert board members whom it wishes to recruit to accompany its development in the years to come. The Ordinary and Extraordinary Shareholders' Meeting will also be the occasion to implement the provisions of the "Copé-Zimmermann" law (relating to the balanced representation of men and women on corporate boards), and the shareholders will vote on the proposed nomination of Ms. Catherine Larue and Ms. Anne-Hélène Monsellato as directors of the Company.  Additional biographical information, including the experience and expertise of these candidates in included below. As also indicated in the April 24, 2017 press release, and subject to the approval of the shareholders of the change in the type of administration of the Company and the composition of the new Board of Directors, the current Chairman of the Executive Board is proposed to be appointed Chairman of the Board of Directors and Chief Executive Officer of the Company. In addition to the usual items on the agenda related to the review of the financial statements and the different reports of the Executive and Supervisory Boards and the Statutory Auditors for the 2016 fiscal year, the Executive Board is proposing a certain number of alternative draft resolutions that differ depending on the decision of the shareholders with respect to the change in type of administration of the Company.  Depending on this decision, only those draft resolutions relating to the specific type of administration chosen will be submitted to a vote of the shareholders. The resolutions submitted to the shareholders are grouped together in the following manner: Additional information is available in the convening notice dated May 12, 2017, which is available on the Company's website.  All of the documentation concerning the Ordinary and Extraordinary Shareholders' Meeting (including the Say on Pay report pursuant to the Sapin II Law) will be made available to shareholders in accordance with current regulations and also available on the Company's website by May 19, 2017. Dr. Catherine Larue has been CEO ad interim of Luxembourg Institute of Health (LIH), a biomedical research institute, since January 2016. From 2012 to end 2015, she was CEO of the Integrated Biobank of Luxembourg (IBBL), where she led the development of the biobanking strategy and new initiatives in the field of personalized medicine. Prior to joining the IBBL, Dr. Larue piloted the biomarker program at Genfit until 2012. Dr. Catherine Larue began her career as team leader at Sanofi at the Montpellier, France based R&D center in the cardiovascular research department.  She later joined Sanofi Diagnostics Pasteur Inc., in Minnesota, United States, where she ran the immunology department for three years, developing tests and instruments.  She thereafter returned to Paris, France as Director at Sanofi Diagnostics Pasteur, and then spent 11 years at the Bio-Rad group, holding different management positions.  She participated in the discovery of several innovative biomarkers and the commercialization of dozens of diagnostic products. Dr. Catherine Larue is the author of 85 articles and has filed 13 patents.  She holds a doctorate in experimental biology and an accreditation to direct research (Habilitation à Diriger la Recherche or HDR) from the University of Rouen, a degree in clinical oncology from the University of Paris VI and an executive MBA from St John's University (New York).  In 2014, she was voted Luxembourg's most inspiring woman of the year in the "Science, Technology and Research" category. Anne-Hélène Monsellato is a Certified Public Accountant in France since 2008 and graduated from EM Lyon in 1990 with a degree in Business Management. Since May 2015, she has been an independent director, the Chairman of the Audit and Risk Committee and a member of the Corporate Governance and Nomination Committee of Euronav, a Belgian crude oil tanker company listed on NYSE and Euronext Brussels.  In addition, she serves as the Vice President and Treasurer of the Mona Bismarck American Center for Art and Culture, a U.S. public foundation based in New York. From 2005 until 2013, Mrs. Monsellato served as a Partner with Ernst & Young (now EY), Paris, after having served as Auditor/Senior, Manager and Senior Manager for the firm starting in 1990. During her time at EY, she gained extensive experience in cross border listing transactions, in particular with the U.S., internal control and risk management, and was involved with several companies in the pharmaceutical and biotechnology sector. Mrs. Monsellato is an active member of the French Association of Directors (IFA) and of the selection committee of Femmes Business Angels since 2013. GENFIT is a biopharmaceutical company focused on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatment and an increasing number of patients worldwide. GENFIT's R&D efforts are focused on bringing new medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver (such as NASH - Nonalcoholic steatohepatitis) and more generally the gastro-intestinal arena. GENFIT's approach combines novel treatments and biomarkers. Its lead proprietary compound, elafibranor, is currently in a Phase 3 study. With facilities in Lille and Paris, France, and Cambridge, MA (USA), the Company has approximately 130 employees. GENFIT is a public company listed in compartment B of Euronext's regulated market in Paris (Euronext: GNFT - ISIN: FR0004163111). www.genfit.com This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, including related to biomarkers, progression of, and results of clinical data from, the RESOLVE-IT trial, review and approvals by regulatory authorities, such as the FDA or the EMA, regarding in particular, elafibranor in NASH and PBC, as well as other indications, and biomarkers, the success of any inlicensing strategies, the Company's continued ability to raise capital to fund its development, as well as those discussed or identified in the Company's public filings with the AMF, including those listed under Section 4 "Main Risks and Uncertainties" of the Company's 2016 Registration Document registered with the French Autorité des marchés financiers on April 28, 2017 under n° R.17-034, which is available on GENFIT's website (www.genfit.com) and on the website of the AMF (www.amf-france.org). Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in GENFIT in any country. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.


GENFIT: CONVENING NOTICE TO THE ORDINARY AND EXTRAORDINARY SHAREHOLDERS MEETING ON JUNE 16, 2017 Lille (France), Cambridge (Massachusetts, United States), May 12, 2017 - GENFIT (Euronext: GNFT - ISIN: FR0004163111), a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announced that it has published today in today's French legal announcements bulletin (Bulletin des Annonces Légales Obligatoires) its convening notice to the Ordinary and Extraordinary Shareholders' Meeting to be held on Friday, June 16, 2017 at 10:30 am at the University of Lille College of Pharmaceutical and Biological Science located at Parc Eurasanté, 3, rue du Professeur Laguesse in Lille (59000), France. As indicated in its press release on April 24, the shareholders will be invited to vote on the change in the type of administration of the Company, moving from a two-tiered board (Supervisory Board and Executive Board) to a single board structure (Board of Directors). The Company considers that this change will allow it to be closer to international standards and to welcome the expert board members whom it wishes to recruit to accompany its development in the years to come. The Ordinary and Extraordinary Shareholders' Meeting will also be the occasion to implement the provisions of the "Copé-Zimmermann" law (relating to the balanced representation of men and women on corporate boards), and the shareholders will vote on the proposed nomination of Ms. Catherine Larue and Ms. Anne-Hélène Monsellato as directors of the Company.  Additional biographical information, including the experience and expertise of these candidates in included below. As also indicated in the April 24, 2017 press release, and subject to the approval of the shareholders of the change in the type of administration of the Company and the composition of the new Board of Directors, the current Chairman of the Executive Board is proposed to be appointed Chairman of the Board of Directors and Chief Executive Officer of the Company. In addition to the usual items on the agenda related to the review of the financial statements and the different reports of the Executive and Supervisory Boards and the Statutory Auditors for the 2016 fiscal year, the Executive Board is proposing a certain number of alternative draft resolutions that differ depending on the decision of the shareholders with respect to the change in type of administration of the Company.  Depending on this decision, only those draft resolutions relating to the specific type of administration chosen will be submitted to a vote of the shareholders. The resolutions submitted to the shareholders are grouped together in the following manner: Additional information is available in the convening notice dated May 12, 2017, which is available on the Company's website.  All of the documentation concerning the Ordinary and Extraordinary Shareholders' Meeting (including the Say on Pay report pursuant to the Sapin II Law) will be made available to shareholders in accordance with current regulations and also available on the Company's website by May 19, 2017. Dr. Catherine Larue has been CEO ad interim of Luxembourg Institute of Health (LIH), a biomedical research institute, since January 2016. From 2012 to end 2015, she was CEO of the Integrated Biobank of Luxembourg (IBBL), where she led the development of the biobanking strategy and new initiatives in the field of personalized medicine. Prior to joining the IBBL, Dr. Larue piloted the biomarker program at Genfit until 2012. Dr. Catherine Larue began her career as team leader at Sanofi at the Montpellier, France based R&D center in the cardiovascular research department.  She later joined Sanofi Diagnostics Pasteur Inc., in Minnesota, United States, where she ran the immunology department for three years, developing tests and instruments.  She thereafter returned to Paris, France as Director at Sanofi Diagnostics Pasteur, and then spent 11 years at the Bio-Rad group, holding different management positions.  She participated in the discovery of several innovative biomarkers and the commercialization of dozens of diagnostic products. Dr. Catherine Larue is the author of 85 articles and has filed 13 patents.  She holds a doctorate in experimental biology and an accreditation to direct research (Habilitation à Diriger la Recherche or HDR) from the University of Rouen, a degree in clinical oncology from the University of Paris VI and an executive MBA from St John's University (New York).  In 2014, she was voted Luxembourg's most inspiring woman of the year in the "Science, Technology and Research" category. Anne-Hélène Monsellato is a Certified Public Accountant in France since 2008 and graduated from EM Lyon in 1990 with a degree in Business Management. Since May 2015, she has been an independent director, the Chairman of the Audit and Risk Committee and a member of the Corporate Governance and Nomination Committee of Euronav, a Belgian crude oil tanker company listed on NYSE and Euronext Brussels.  In addition, she serves as the Vice President and Treasurer of the Mona Bismarck American Center for Art and Culture, a U.S. public foundation based in New York. From 2005 until 2013, Mrs. Monsellato served as a Partner with Ernst & Young (now EY), Paris, after having served as Auditor/Senior, Manager and Senior Manager for the firm starting in 1990. During her time at EY, she gained extensive experience in cross border listing transactions, in particular with the U.S., internal control and risk management, and was involved with several companies in the pharmaceutical and biotechnology sector. Mrs. Monsellato is an active member of the French Association of Directors (IFA) and of the selection committee of Femmes Business Angels since 2013. GENFIT is a biopharmaceutical company focused on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatment and an increasing number of patients worldwide. GENFIT's R&D efforts are focused on bringing new medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver (such as NASH - Nonalcoholic steatohepatitis) and more generally the gastro-intestinal arena. GENFIT's approach combines novel treatments and biomarkers. Its lead proprietary compound, elafibranor, is currently in a Phase 3 study. With facilities in Lille and Paris, France, and Cambridge, MA (USA), the Company has approximately 130 employees. GENFIT is a public company listed in compartment B of Euronext's regulated market in Paris (Euronext: GNFT - ISIN: FR0004163111). www.genfit.com This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, including related to biomarkers, progression of, and results of clinical data from, the RESOLVE-IT trial, review and approvals by regulatory authorities, such as the FDA or the EMA, regarding in particular, elafibranor in NASH and PBC, as well as other indications, and biomarkers, the success of any inlicensing strategies, the Company's continued ability to raise capital to fund its development, as well as those discussed or identified in the Company's public filings with the AMF, including those listed under Section 4 "Main Risks and Uncertainties" of the Company's 2016 Registration Document registered with the French Autorité des marchés financiers on April 28, 2017 under n° R.17-034, which is available on GENFIT's website (www.genfit.com) and on the website of the AMF (www.amf-france.org). Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in GENFIT in any country. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.

Loading Biological Science Inc. collaborators
Loading Biological Science Inc. collaborators